Molecular screening of patients with long standing extensive ulcerative colitis: detection of p53 and Ki-\textit{ras} mutations by single strand conformation polymorphism analysis and differential hybridisation in colonic lavage fluid

S M Lang, D F Stratakis, M Heinzlmann, W Heldwein, B Wiebecke, K Loeschke

Abstract

Background—In patients with long standing ulcerative colitis at risk of developing malignancy, mutations of the p53 and Ki-\textit{ras} gene were investigated in lavage solution obtained at surveillance colonoscopy.

Methods—DNA was isolated from 31 consecutive patients with total or subtotal ulcerative colitis and a disease duration of between seven and 26 years. Twenty seven control patients showed no macroscopic or microscopic inflammation on colonoscopy. Exons 5–8 of the p53 gene and exon 1 of the Ki-\textit{ras} gene were amplified by polymerase chain reaction. Mutations of the p53 gene were detected by single strand conformation polymorphism analysis. Point mutations of the Ki-\textit{ras} gene were hybridised on dot blots with oligonucleotides marked with digoxigenin.

Results—In all cases of ulcerative colitis and in all of the 27 control patients, wild type p53 and wild type Ki-\textit{ras} could be detected. In four patients with ulcerative colitis, a mutation in exon 5 to 7 of the p53 gene was found, and two patients had a mutation of the Ki-\textit{ras} gene (Gly to Asp-12, Gly to Val-12). None of these patients had dysplasia in serial biopsy specimens, and all but one had had the disease for more than 10 years. One control patient had a mutation.

Conclusions—Mutations were more frequent in patients with long standing ulcerative colitis (19\%) than in control patients (3\%, \(p = 0.07\)). The technique may be useful for screening for early malignancy in ulcerative colitis.

(Gut 1999;44:822-825)

Keywords: p53; K-\textit{ras}; colonic lavage; ulcerative colitis; molecular screening

One of the major clinical concerns in the treatment of patients with long standing ulcerative colitis is to identify those patients who are at increased risk of malignant transformation. Widely accepted classical risk factors are long disease duration (more than 7–10 years) and involvement of the entire large intestine (pancolitis).1–3 Repeated colonoscopy with sequential biopsies is recommended as a surveillance procedure. The aim is to detect epithelial cell dysplasia as an early indicator of malignancy, because survival can be prolonged if surgery is performed before the tumour has reached an advanced stage.4,5 However, the histological grading of dysplasia (mild to severe) has limitations such as interobserver variability, confounding inflammatory changes, and particularly the random nature of biopsies.1–4

The identification of genetic alterations characterising malignant transformation is a promising new diagnostic approach. The first successful attempt to identify gene mutations in stool from patients with colorectal carcinoma or adenoma was reported by Sidransky et al.,7 followed by several other investigators.8–16 A major disadvantage of this approach in early colitis carcinoma may be a small tumour load—that is the content of malignant cells in the stool—and impurities acting as polymerase chain reaction (PCR) inhibitors. On the other hand, colonic effluent samples contain less contaminants, can be expected to harbour epithelial cells shed from all sections of the intestine, and provide a convenient source of DNA.

Tobi et al.13 were able to detect Ki-\textit{ras} mutations in colonic flushings of patients with a history of colorectal carcinoma, who had no apparent tumour at the time of the investigation. We have shown that colonoscopic lavage solution collected during routine colonoscopy is suitable for the analysis of mutant p53 and Ki-\textit{ras} in a small series of patients with long standing ulcerative colitis.15–16

The present investigation was carried out to study mutant p53 and Ki-\textit{ras} in a larger series of patients with long standing extensive colitis and to correlate these findings with disease duration, clinical severity during the course of the illness, and current morphological activity. Control patients without colonic inflammation were similarly investigated.

Methods

PATIENT CHARACTERISTICS

Thirty one patients (17 women and 14 men, mean (SD) age 39 (10) years) with a history of total or subtotal ulcerative colitis were studied (table 1). Patients were grouped according to

Abbreviations used in this paper: PCR, polymerase chain reaction; SSCP, single strand conformation polymorphism.
Table 1  Clinical characteristics of controls and patients with ulcerative colitis for the number of years indicated

<table>
<thead>
<tr>
<th>Disease duration</th>
<th>7–9 years</th>
<th>10–15 years</th>
<th>&gt; 15 years</th>
<th>Σ</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number</td>
<td>11</td>
<td>10</td>
<td>8</td>
<td>31</td>
</tr>
<tr>
<td>Age (years)</td>
<td>38 (11)</td>
<td>35 (9)</td>
<td>44 (8)</td>
<td>39 (10)</td>
</tr>
<tr>
<td>Sex (F/M)</td>
<td>7/6</td>
<td>6/4</td>
<td>4/4</td>
<td>17/14</td>
</tr>
<tr>
<td>Disease severity</td>
<td>11/2</td>
<td>2/2</td>
<td>11/15</td>
<td>15/12</td>
</tr>
<tr>
<td>Mild</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>3</td>
</tr>
<tr>
<td>Moderate</td>
<td>2</td>
<td>0</td>
<td>1</td>
<td>3</td>
</tr>
<tr>
<td>Severe</td>
<td>8</td>
<td>5</td>
<td>3</td>
<td>16</td>
</tr>
<tr>
<td>Backwash ileitis</td>
<td>6</td>
<td>2</td>
<td>1</td>
<td>3</td>
</tr>
<tr>
<td>Primary sclerosing cholangitis</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Haemorrhoids</td>
<td>7</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diverticulosis</td>
<td>6</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Irritable colon</td>
<td>3</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Normal mucosa</td>
<td>11</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Results are mean (SD) at time of colonoscopy.

Disease duration (7–9 years, 10–15 years, and more than 15 years), disease “severity”, and morphological activity at the time of colonoscopy. As a measure of disease severity, the drug treatment employed during the course of the disease was assessed. The disease was classified as mild when patients had been treated with salicylates alone (three cases), moderate when corticosteroids were employed (13 cases), and severe when immunosuppressives (usually azathioprine and corticosteroids) were given (15 cases). Current disease activity was assessed semiquantitatively by the endoscopist and the pathologist using conventional criteria. Colonoscopic classification of macroscopic disease was assessed as no significant activity in the presence of mild inflammation with loss of vascular pattern or moderate activity (defined as severe inflammation with contact bleeding), and severe activity (defined as more severe disease with friability, ulcers, or spontaneous bleeding). Pathological grading ranged from mild activity (defined as mild oedema and inflammation) to moderate activity (defined as crypt abscess formation) to severe activity with active ulceration. Three patients presented with backwash ileitis and none had primary sclerosing cholangitis.

Twenty seven control patients (15 women and 12 men, mean age 53 (15) years) showed no macroscopic or microscopic inflammation on colonoscopy (14 had no pathological findings including three with irritable bowel syndrome, seven with haemorrhoids, and six with diverticulosis).

All patients and controls gave informed consent to participate in the study, which was approved by the local ethics committee.

PROCESSING OF SAMPLES

The preparation for colonoscopy included a low fibre diet for 24 hours and a laxative taken on the day before and lavage solution taken on the day of colonoscopy until the rectal discharge became clear. All of the lavage solution remaining in the colon (about 300–500 ml) was collected endoscopically in single-use or autoclaved containers. Two biopsy specimens were routinely taken every 10 cm and sent to the pathologist for histological assessment. Two additional specimens were taken at random for DNA analysis.

Lavage fluid was centrifuged at 2700 g; the cell-free supernatant was discarded and the solid material resuspended in phosphate buffered saline. This was repeated three times until the supernatant was clear. The sediment was then stored at −20°C.

DNA ANALYSIS

For DNA extraction a DNA isolation kit (DNA isolation kit USB; Amersham, Braunschweig, Germany) was used and the DNA yield was determined photometrically at 260 nm and 280 nm.

Exon 5–8 of the p53 gene and codon 12 and 13 on exon 1 of the Ki-ras oncoprotein were amplified by PCR using the protocol published previously. Controls were subjected to the same procedure.

Mutations of the p53 gene were analysed by single strand conformation polymorphism (SSCP) analysis of amplified DNA. After non-denaturing polyacrylamide gel electrophoresis, DNA bands were visualised with a 0.1% silver stain and band size was assessed by comparison with known standard DNA (123 bp DNA ladder; Gibco BRL, Bethesda, Maryland, USA) (fig 1). A preparation of wild type DNA from peripheral leucocytes of healthy volunteers served as negative control. As positive controls, DNA was extracted from the cultured epithelial cell line HaCaT with known mutations in exon 5 and 8 on chromosome 17p.

For the detection of Ki-ras mutations, DNA was blotted on to positively charged nylon membranes (Boehringer, Mannheim, Germany). Identical membranes were hybridised simultaneously with different detection oligonucleotides labelled with digoxigenin (MWG Biotech, Munich, Germany). The signal was detected by chemiluminescence on superimposed x ray film with anti-digoxigenin-alkaline phosphatase Fab fragments. DNA from colorectal carcinoma specimens with known mutations of codon 12 served as positive control. Direct sequencing (both automated and manual) was performed on PCR products of the lavage solution containing a mutation of either the Ki-ras or the p53 gene (MWG Biotech).

Figure 1  Single strand conformation polymorphism analysis of amplified DNA from three cases. In cases 1 and 2, only wild type p53 is present. In case 3, there is an additional band (arrow), indicating a mutation in the p53 gene.
Results are expressed as mean (SD). Statistical comparisons between the groups were performed using the Pearson $\chi^2$ test. Significance was accepted at a $p<0.05$ level.

**Results**

**p53 and Ki-ras mutations in colonic flushings**

In all samples from patients with ulcerative colitis or control patients, we were able to detect the p53 and wild type Ki-ras genes (figs 1 and 2), whereas all controls without DNA (contamination controls) yielded no signal. SSCP analysis of the p53 gene showed four mutations in exon 5, 6, or 7. Two of the patients with ulcerative colitis had a mutation of the Ki-ras oncogene, one Gly to Asp-12 and one Gly to Val-12 (fig 2, table 2). All detected mutations of the Ki-ras and p53 genes were confirmed by direct sequencing. All but one of the patients had long standing disease of more than 10 years duration (table 2); the one patient with a shorter duration (eight years) and a p53 mutation had severe disease. Three patients had backwash ileitis and one had a Ki-ras mutation. One of the control patients had a mutation of the p53 gene. This patient (haemorrhoids, female, 56 years of age) without macroscopic or microscopic abnormalities in the colon had a family history of pancreatic cancer but no evidence of tumour on thorough examination. She remained healthy for more than 12 months of follow up.

Taken together, 19% of the patients with ulcerative colitis had p53 or Ki-ras mutations as opposed to 3% of the controls ($p = 0.07$).

**Histological assessment of colonic biopsy samples**

From the biopsy samples sent to the pathologist, mild dysplasia was detected in four patients. None of these patients had a mutation in the lavage fluid. In two cases the endoscopist described a suspicious lesion but no dysplasia was found on pathological assessment. None of the patients with a mutation in the lavage had dysplasia in the mucosal biopsy specimens.

**Ki-ras and p53 mutations in colonic biopsy specimens**

In all cases of dysplasia reported by the pathologist, and in those in which a mutation was found, DNA was extracted from random specimens. A mutation of the Ki-ras gene could not be detected in any of the specimens, although in both those from patients in which a mutation was found in the lavage fluid, sufficient DNA was extracted and the wild type serving as an internal control was detectable. The SSCP analysis of the p53 gene of all four ulcerative colitis samples showed no mutation in the biopsy samples, although sufficient DNA was amplified for SSCP analysis. All samples from cases of dysplasia remained negative when analysed for both p53 and Ki-ras mutations.

Discussion

In the present study we analysed colonic flushings from 31 patients with long standing ulcerative colitis using molecular screening tools, because mutations may be useful surrogate markers of early neoplasia. The method is based on the observation that cytological specimens collected from the large intestine are not only suitable for cytological assessment but also for the analysis of genetic changes using PCR amplification. This approach offers the advantage that cells shed from the entire colon (and probably the small intestine) can be analysed, as mutations have been detected in caecum tumours with the same probability as more distal tumours.

In our series we found mutations of the p53 gene in four patients (13%) and Ki-ras mutations in two (6%). There was no correlation with disease severity or morphological activity in this small series, with an uneven distribution between groups.

However, all patients carrying a mutation, except one, had had the disease for more than 10 years, which is in accordance with clinical experience that long disease duration is one of the major risk factors for the development of carcinoma in these patients.

In our patients, we were unable to correlate mutations found in the lavage with dysplastic...
changes observed histopathologically. The fact that no
dysplasia was detected in the serial biopsy samples from patients exhibiting
mutations in the lavage may be due to the random
nature of the biopsies as opposed to a more
representative sampling in the lavage. It may also
be that a small number of mutant cells may
not be recovered in the lavage by our methods.

Primary sclerosing cholangitis and back-
wash ileitis have both been reported as additional
risk factors for developing colitis carcinoma.
None of our patients had primary sclerosing
cholangitis, but three had backwash ileitis. One
of the latter patients carried a Ki-ras mutation
(Gly to Val-12).

Interestingly we were able to detect the wild
type Ki-ras and p53 in all normal controls,
although the amount of cells shed is probably
much smaller than in inflammation or neoplas-
ia. In controls we found a mutation in only one
case. The clinical meaning of this finding
remains unclear, with this patient remaining
well after follow up for one year. In the series of
Tobi et al., in one patient, effluent was found to
harbour a mutant Ki-ras allele four years before
colorectal cancer was diagnosed.

A review of the literature shows that the risk of
malignant transformation in extensive ulcer-
ative colitis begins after 7–10 years and may
reach about 10% after 25 years. Essentially
the same genetic lesions are found in
 tumours developing in long standing ulcerative
colitis as in sporadic colonic carcinoma. However, apart from the data presented here,
there have only been anecdotal data on the
occurrence of mutations in patients with
ulcerative colitis but without an apparent
tumour. In long standing ulcerative colitis, we
cannot be fully content with present cancer
screening modalities based on the search for
dysplasia. Our data show that it is possible to
use colonic lavage fluid for molecular analyses
and indicate that with longer disease duration
p53 and Ki-ras mutations become more
frequent.

Therefore it appears reasonable to evaluate
this diagnostic tool in a larger number of
patients at risk. However, a note of caution is
required when molecular screening tests are
employed, because there is a false negative rate.
In the end, only long term follow up can show
whether molecular markers are suitable tools
for predicting neoplastic transformation in
these patients.

We would like to thank Professor Zoller and his team for the
contribution of two cases. The work was supported by grant no
8232111, from Wilhelm Viallant Stiftung, Munich, Germany.
Further support was given by Ferring GmbH, Reil and Falk
Foundation, Freiburg, Germany. Part of this work was
performed by Diana Stratakis (inaugural dissertation).

1 Gillen CD, Wainsztein RS, Prior P, et al. Ulcerative colitis and
Crohn’s disease: a comparison of the colorectal cancer risk
and cancer in extensive ulcerative colitis: findings among
3 Lasch HA, Silverstein MD, Hanauer SB. Hazard rates for
dysplasia and cancer in ulcerative colitis. Results from a
4 Choi PM, Nagent PW, Schoet DJ, et al. Colonic surveillance
reduces mortality from colorectal cancer in ulcerative colitis.
5 Lennard-Jones JE. Colitic cancer: supervision, surveillance,
6 Blackstone MO, Raddi RH, Rogers BH, et al. Dysplasia-
associated lesion or mass (DALM) detected by colonoscopy
in long-standing ulcerative colitis: an indication for colectomy.
7 Sidrys D, Tokino T, Hamilton SR, et al. Identification of
r ras oncogene mutations in the stool of patients with curable
8 Koornstra JJ, Rokke O, Halvorsen JF, et al. Determination of
the activated proto-oncogene (Ki-ras) in faeces. A new
laboratory analysis for early diagnosis of colorectal cancer.
Tidsskr Nor Laegeforen 1995;115:3266–70.
9 Villa E, Dugani A, Rebecchi AM, et al. Identification of sub-
jects at risk for colorectal carcinoma through a test based
on Ki-ras determination in the stool. Gastroenterology 1996;
110:1346–53.
mutations in stools of patients with colorectal cancer by
12 Eguchi S, Kohara N, Komuta K, et al. Mutations of the p53
gene in the stool of patients with resectable colorectal cancer.
13 Tobi M, Luo FC, Ronai Z. Detection of Ki-ras mutation in
colonic effluent samples from patients without evidence of
14 Hasegawa Y, Takeda S, Ichii S, et al. Detection of Ki-ras
mutations in DNAs isolated from feces of patients with
colorectal tumors by mutant-allele-specific amplification
mutation from neoplastic colonic cells exfoliated in feces.
16 Lang SM, Heinzlmann M, Stratakis DF, et al. Detection of
Ki-ras mutations by PCR and differential hybridization and of
p53 mutations by SSCP analysis in endoscopically obtained
lavage solution from patients with long-standing ulcerative
17 Gomes P, Du Boulay C, Smith CL, et al. Comparison of
detection of DNA mutations and exfoliative cytology
between disease activity indices and colonoscopic findings
in patients with colonic inflammatory bowel disease. Gut
single strand conformation polymorphism (SSCP) analysis with
broad applicability: a study on the effects of acrylamide, buffer
and glycerol concentrations in SSCP analysis of p53 gene
exons. Eur J Clin Chem Clin Bio-
keratinization in a spontaneously immortalized aneuploid
20 Bader GM, Papanicolaou GN. The application of cytology
in the diagnosis of cancer of the rectum, sigmoid and
21 Raskin HF, Palmer WL, Ratner JB. Exfoliative cytology in
diagnosis of cancer of the colon. Dis Colon Rectum 1959;2:
46–57.
22 Kelly P, Patchett S, McCloskey D, et al. Sclerosing cholangi-
23 Von-Heerbay A, Otto HF. Backwash ileitis in ulcerative
24 Ekbom A, Helmick C, Zach M, et al. Ulcerative colitis and
25 Katkia I, Brydy RS, Morris E, et al. Assessment of colorec-
tal cancer risk in patients with ulcerative colitis: experience
26 Kern SE, Redston M, Seymour AB, et al. Molecular genetic
profiles of colitis-associated neoplasms. Gastroenterology
perceptions of dysplasia and approaches to surveillance
Molecular screening of patients with long standing extensive ulcerative colitis: detection of p53 and Ki-ras mutations by single strand conformation polymorphism analysis and differential hybridisation in colonic lavage fluid

S M Lang, D F Stratakis, M Heinzlmann, W Heldwein, B Wiebecke and K Loeschke

Gut 1999 44: 822-825
doi: 10.1136/gut.44.6.822